Abstract: Bimetal-incorporated mesoporous silicate catalysts are provided. In embodiments, such a catalyst comprises a silicate lattice, a first transition metal M, and a second transition metal M?, wherein M and M? are selected from Zr, Nb, and W and are directly incorporated into the silicate lattice such that M and M? replace Si atoms. Methods of using the catalysts are also provided, including in methods for dehydrating alcohols. Methods of making the catalysts are also provided.

Abstract: A general mounting method for ducted fan propulsors is disclosed. This mounting method uses extremely slender stators that connect the duct ring to the propulsor which is mounted in the middle and drives the rotor, fan or propeller. The slender stators take the form of spokes and as such are so slender that the midspan stresses within the spokes are dominated by axial tension loads rather than the shear loads experienced by conventional stators. The spokes may have an aerodynamic shape and damping methods may be used to retard spoke vibrations and transmission of engine vibrations to the duct and force. The duct itself is also stiffened by the spoke arrangement, thereby reducing low frequency vibration modes.

Abstract: The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.

Abstract: The disclosure provides human toll-like receptor modulators of general Formula (II), wherein R1, R2, R3, R4, R5, R6, R7, R8 are defined herein.

Abstract: The present technology relates generally to compositions and methods for creating recombinant T cell receptor (TCR) libraries and methods of their therapeutic use. The compositions and methods of the present technology are useful for rapid isolation of antigen-specific TCR repertoires as personalized, targeted therapies for cancer and viral infection.

Abstract: A recombinant mutant BoV genome is provided, as well as methods of using the vector, e.g., to prepare helper-free virus.

Abstract: Described herein is a method. The method may include receiving, by a first device, data of a first layer of the first device, the data for transmission over a network to a second device. The method may include encrypting, by the first device, the data at the first layer, to generate first encrypted data. The method may include encrypting, by the first device, the first encrypted data at a second layer, to generate second encrypted data. The method may include transmitting, by the first device, the second encrypted data via the network to the second device.

Abstract: A barrier system is provided for use in reducing infections associated with post-operative surgical incision and/or a percutaneous medical device, such as a catheter, that is disposed within the surgical incision. Such a barrier system may include: a barrier device having a skin-contacting surface and a catheter-receiving surface; and an adhesive composition configured for adhering to skin, the barrier device, and/or the catheter so as to form a barrier at or adjacent to an incision in the skin where the catheter is percutaneously inserted through the skin. A tensioning anchor and associated system of two or more tensioning anchors is provided for post-operative wound closure. A method for applying and removing the barrier device and tensioning anchors is also provided.

Abstract: A non-human organism for upgrading intermediate oxidation products formed by catalytic degradation of alkanes or polystyrenes is provided. The non-human organism is genetically modified to convert the intermediate oxidation products to secondary metabolites, and in particular to include a positive feedback loop construction in the promotor system. A method includes steps of catalytically degrading alkanes or polystyrene in an oxidizing environment to form intermediate products with one or more catalysts and contacting the intermediate products with the non-human organism such that intermediate oxidation products are converted to secondary metabolites.

Abstract: Haloalkane sulfonic acids and salts thereof are provided. In embodiments, a haloalkane sulfonic acid or salt thereof comprises an alkyl group, at least one sulfonic acid group, and one or more halogens selected from Cl, Br, I, and F, the haloalkane sulfonic acid having a total number of carbon atoms of from 2 to 9, and wherein if at least one F atom is present, the haloalkane sulfonic acid comprises at least one other halogen selected from Cl, Br, and I. Methods of making and using the haloalkane sulfonic acids/salts are also provided.

Abstract: The present disclosure provides conjugates, methods of making the same, and uses thereof. The conjugates of the present technology are useful in inducing anergy in insulin-binding B cells.

Abstract: Aerial vehicles, their structures and methods of locomotion are described. An aerial vehicle may include a fuselage having an x-axis, a plurality of flexible structures emanating from the fuselage that take the form of a feather, wing and/or tentacle, at least one motor, and at least one propeller driven by one or more motors. Each flexible structure may extend from a fuselage in any direction and are used to enhance the observability of the aircraft by moving and/or oscillating within a frequency band and at a magnitude that is more easily observed by and catches the human eye.

Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.

Abstract: A method of treating amyotrophic lateral sclerosis (ALS) is provided to extend life expectancy in a subject. The method can include administering the ketamine to a subject having ALS such that the subject has an extended life expectancy compared to life expectancy of the subject prior to being administered the ketamine. The extended life expectancy is determined by the subject having a first progression rate of ALS prior to being administered ketamine and a second progression rate of ALS after being administered ketamine. The first progression rate is faster than the second progression rate such that the progression of ALS in the subject is slowed by the ketamine.

Abstract: A method of evaluating a cerebrovascular health of a patient includes causing a patient to exercise for an exercise duration at an exercise intensity, collecting cerebrovascular information from the patient during the exercise duration, collecting cardiovascular information from the patient during the exercise duration, correlating the cerebrovascular information to the cardiovascular information to create a correlated cerebrovascular curve, and determining a cerebrovascular health and viability for cerebrovascular therapy.

Abstract: The present application relates to stacked piezoelectric energy harvesters that include compliant layers between piezoelectric layers. The energy harvesters are useful in various structures and devices, including tissue-stimulating implants, such as spinal fusion implants. The present application also relates to methods of increasing the power output of a piezoelectric energy harvester through the inclusion of compliant layers.

Abstract: This disclosure generally relates to aerial vehicles that may convert from hover-mode to missile-mode flight and back via body tilt for efficient flight and can strike wires such that neither the wires nor the aircraft are damaged, and divergence is prevented. This includes an aerial vehicle having an elongate fuselage having a nose tip, a plurality of engines connected to the fuselage, and at least three protective members connected substantially near the nose tip of the fuselage longitudinally beyond the plurality of engines.

Abstract: Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.